|
|
|
|
| LEADER |
01573 am a22001693u 4500 |
| 001 |
138782.2 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Ghattas, Majed
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biological Engineering
|e contributor
|
| 700 |
1 |
0 |
|a Dwivedi, Garima
|e author
|
| 700 |
1 |
0 |
|a Lavertu, Marc
|e author
|
| 700 |
1 |
0 |
|a Alameh, Mohamad-Gabriel
|e author
|
| 245 |
0 |
0 |
|a Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities
|
| 260 |
|
|
|b Multidisciplinary Digital Publishing Institute,
|c 2022-01-03T18:24:16Z.
|
| 856 |
|
|
|z Get fulltext
|u https://hdl.handle.net/1721.1/138782.2
|
| 520 |
|
|
|a Vaccination is a key component of public health policy with demonstrated cost-effective benefits in protecting both human and animal populations. Vaccines can be manufactured under multiple forms including, inactivated (killed), toxoid, live attenuated, Virus-like Particles, synthetic peptide, polysaccharide, polysaccharide conjugate (glycoconjugate), viral vectored (vector-based), nucleic acids (DNA and mRNA) and bacterial vector/synthetic antigen presenting cells. Several processes are used in the manufacturing of vaccines and recent developments in medical/biomedical engineering, biology, immunology, and vaccinology have led to the emergence of innovative nucleic acid vaccines, a novel category added to conventional and subunit vaccines. In this review, we have summarized recent advances in vaccine technologies and platforms focusing on their mechanisms of action, advantages, and possible drawbacks.
|
| 655 |
7 |
|
|a Article
|
